Rifaat Safadi

Jerusalem, JM 91120, Israel

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 108 publications

Epigenetic Alterations in Hepatocellular Carcinoma: Mechanisms and Biomarkers for Precision Therapy.

Epigenetic Alterations in Hepatocellular Carcinoma: Mechanisms and Biomarkers for Precision Therapy.

Journal: Cancers

Published: June 01, 2026

Consensus on standardized later-line systemic therapy for hepatocellular carcinoma.

Consensus on standardized later-line systemic therapy for hepatocellular carcinoma.

Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy

Published: May 11, 2026

MiR-122 regulates liver tolerance.

MiR-122 regulates liver tolerance.

Journal: JHEP reports : innovation in hepatology

Published: March 18, 2026

Efficacy and safety of belapectin for the prevention of esophageal varices in patients with MASH cirrhosis: The randomized, placebo-controlled NAVIGATE trial.

Efficacy and safety of belapectin for the prevention of esophageal varices in patients with MASH cirrhosis: The randomized, placebo-controlled NAVIGATE trial.

Journal: Hepatology (Baltimore, Md.)

Published: February 25, 2026

Mitochondrial NCLX couples glucagon- and PDE2A-dependent signals to regulate hepatic lipid metabolism.

Mitochondrial NCLX couples glucagon- and PDE2A-dependent signals to regulate hepatic lipid metabolism.

Journal: Molecular metabolism

Published: January 27, 2026

Hepatitis B Vaccine Response in Children of Vaccinated Versus Unvaccinated Mothers: A Retrospective Cohort Study.

Hepatitis B Vaccine Response in Children of Vaccinated Versus Unvaccinated Mothers: A Retrospective Cohort Study.

Journal: Journal of viral hepatitis

Published: September 27, 2025

Hepatic Copper Accumulation Predicts Fibrosis Progression and Mortality in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

Hepatic Copper Accumulation Predicts Fibrosis Progression and Mortality in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

Journal: Nutrients

Published: August 05, 2025

Nebokitug, an Anti-chemokine (C-C Motif) Ligand 24 Monoclonal Antibody, in Patients With Primary Sclerosing Cholangitis: A Phase 2 Study.

Nebokitug, an Anti-chemokine (C-C Motif) Ligand 24 Monoclonal Antibody, in Patients With Primary Sclerosing Cholangitis: A Phase 2 Study.

Journal: The American journal of gastroenterology

Published: July 28, 2025

SGLT2 Inhibitors in MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) Associated with Sustained Hepatic Benefits, Besides the Cardiometabolic.

SGLT2 Inhibitors in MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) Associated with Sustained Hepatic Benefits, Besides the Cardiometabolic.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: June 23, 2025

Semaglutide in MASLD Patients: Improved Survival and Liver Outcomes.

Semaglutide in MASLD Patients: Improved Survival and Liver Outcomes.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: May 06, 2025

Insulin Modulates NK Cell Activity in Liver Fibrosis MASH Patients via the STING Pathway.

Insulin Modulates NK Cell Activity in Liver Fibrosis MASH Patients via the STING Pathway.

Journal: Cells

Published: May 05, 2025

Evaluating the influence of maternal anti-HBs status on the antibody levels in vaccinated children.

Evaluating the influence of maternal anti-HBs status on the antibody levels in vaccinated children.

Journal: Clinics and research in hepatology and gastroenterology

Published: March 22, 2025

Showing 1-12 of 108

Last Updated: 09/26/2026